ClinicalTrials.gg
Not yet recruitingNCT07337863SECRET-OAUpdated May 12, 2026

Phase II/III Randomized Trial of UC-MSC Secretome vs Sodium Hyaluronate in Knee Osteoarthritis

A Phase 2/3 interventional study of UC-MSC-Derived Secretome and Sodium Hyaluronate (Hyalein) in Knee Osteoarthritis (Knee OA), sponsored by Universitas Sriwijaya. Not yet recruiting at 1 site in Indonesia. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Universitas Sriwijaya · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee — 4 open to participants now, 4 under way, 2 of them phase 3. Hyaluronic Acid · Osteoarthritis, Knee.

Planned enrollment
10th of 18
50 · median 55
Started
2026
with 2 others
Phase 2/3
3 of 18
1 open now
Registered
16th of 18
by date

Among the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 2/3, and was the 16th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

4 of the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, multicenter Phase II/III clinical trial designed to evaluate the effectiveness and safety of umbilical cord-derived mesenchymal stem cell (UC-MSC) secretome compared with sodium hyaluronate in patients with knee osteoarthritis. Knee osteoarthritis is a common degenerative joint disease that causes chronic pain and functional limitation. Participants will be randomly assigned to receive intra-articular injections of either UC-MSC-derived secretome or sodium hyaluronate. The study aims to assess improvements in knee pain, physical function, and overall clinical outcomes, as well as to evaluate the safety of the interventions over the study period.

Read the detailed description

This multicenter, randomized, double-blind Phase II/III clinical study aims to compare the efficacy and safety of intra-articular UC-MSC-derived secretome with sodium hyaluronate in patients with Kellgren-Lawrence grade 2-3 knee osteoarthritis. Eligible participants will be randomly allocated to one of two treatment arms. Clinical outcomes will be evaluated using validated pain and functional assessment tools at predefined time points. Safety assessments will include monitoring of adverse events throughout the study period. The results of this study are expected to provide evidence regarding the potential role of UC-MSC-derived secretome as an alternative therapeutic option for knee osteoarthritis.

03

Conditions studied

  • Knee Osteoarthritis (Knee OA)

Keywords

  • Knee Osteoarthritis
  • UC-MSC Secretome
  • Randomized Controlled Trial
  • Sodium Hyaluronate
  • Intra-articular Injection
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with primary OA in one or both knees based on American College of Rheumatology (Clinical and Rheumatology criteria). If both knees have OA, the knee with the OA grade that falls within the inclusion criteria (grade 2-3) will be selected. If both knees meet the inclusion criteria, the knee with the highest grade and the one that is most uncomfortable will be chosen.
  2. Males or females in the age range 40-70 years
  3. Symptomatic knee OA (defined by pain at the affected joint for at least 3 months before inclusion and visual analog scale 40 - 70 mm on a 100 mm Visual Analog Scale (VAS).
  4. Radiographic evidence of grade 2 to 3 osteoarthritis (OA) based on Kellgren and Lawrence radiographic criteria.
  5. between 18 - 30 kg/m2
  6. Female participants of childbearing age who agreed to use accepted methods of during the course of the study.
  7. Ability to provide written and willing to participate the study

Exclusion criteria

Exclusion Criteria:

  1. Participants who, based on physical examination and clinical history (anamnesis), are in the active or acute phase of cardiac, pulmonary, hematological, hepatic, renal, systemic , immunodeficiency, or coagulation disorders that may interfere with the administration of the study drug (Secretome or Sodium Hyaluronate) will be excluded,
  2. Diagnosed with a meniscal rupture based on clinical history (anamnesis) and physical examination. If the anamnesis and physical examination show symptoms and signs of a meniscal rupture, further evaluation will be performed using ultrasound (USG),
  3. Participants with significant axial deviation, defined by valgus or varus deformity observed during physical examination, will be excluded,
  4. Participants with other pathological lesions on knee X-rays from the screening examination will also be excluded,
  5. History of any form of secondary arthritis in the knee due to trauma,
  6. History of surgery or major trauma to the knee joint
  7. Has knee effusion,
  8. Has any other inflammatory disorder of the knee joint
  9. Diagnosed with active .
  10. History of stem cell or secretome therapy.
  11. Intra-articular injection of and/or prior treatment with Sodium Hyaluronate and/or rich plasma (PRP) in past 3 months.
  12. Use of NSAIDs and/or chondroprotective supplements, such as glucosamine and chondroitin sulfate, within 7 days before the trial, whether used orally, topically, or via injection,
  13. Undergoing therapy, or anticoagulant therapy, or corticosteroid therapy.
  14. For women of : positive pregnancy test or lactating (females who were planning pregnancy within the next year were excluded).
  15. Enrolled in any other clinical trials within the past four weeks.
  16. The principal investigator considers that the participant is ineligible for the clinical trial due to any reasons other than those listed above
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    UC-MSC-Derived Secretome

    Participants receive intra-articular injection of UC-MSC-derived secretome

    Drug: Sodium Hyaluronate (Hyalein)

  • Active comparator
    Sodium Hyaluronate

    Participants receive intra-articular injection of sodium hyaluronate

    Biological: UC-MSC-Derived Secretome

Interventions

  • BiologicalUC-MSC-Derived Secretome

    Umbilical cord-derived mesenchymal stem cell secretome administered via intra-articular injection according to the study protocol.

  • DrugHyaluronic AcidStudies of Hyaluronic AcidHyaluronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sodium hyaluronate administered via intra-articular injection as an active comparator.

    Also known as: Sodium Hyaluronate

06

What researchers measure

Primary outcomes

  1. Change From Baseline in WOMAC Pain Subscale Score

    Change from baseline in knee pain assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change From Baseline in WOMAC Total Score

    Change from baseline in overall knee pain, stiffness, and physical function assessed using WOMAC total score.

    Time frame: Baseline to Week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the primary and secondary outcome measures, including demographic characteristics, baseline clinical data, outcome scores, and adverse event data, will be shared. All data will be fully anonymized, with no direct identifiers, in accordance with applicable ethical and regulatory requirements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: De-identified individual participant data and supporting documents will be available beginning 6 months after publication of the primary study results and will remain available for up to 5 years.

Access criteria: Access to de-identified IPD will be granted to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study steering committee. Data will be shared under a data use agreement to ensure participant confidentiality and appropriate use of the data.

Data sharing details ↗ · rsmh.go.id

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Sep 2026, 0 months later.

Of 18 phase 2/3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2026
First posted
Jan 13, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Sep 16, 2026
CompletionEst.
Dec 24, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07337863
Lead sponsor
Universitas Sriwijaya
Collaborators
PT Bifarma Adiluhung
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Sep 16, 2026 (estimated)
Completion
Dec 24, 2027 (estimated)
Last update
May 12, 2026

Study contacts

Rudi Erwin Kurniawan, MD, MH
Contact
dr.rudierwin@gmail.com
+6282166114111
Radiyati Umi Partan, MD, PhD
study chair · Universitas Sriwijaya

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion